ZLD — Zelira Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$7.83m
- AU$9.84m
- AU$0.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -244.38% | ||
| Operating Margin | -2278.17% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.86 | 1.04 | 2.09 | 2.89 | 0.55 | 8.37 | 46.08 | -0.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
Directors
- Osagie Imasogie CHM (59)
- Harry Karelis VCH
- Oludare Odumosu MDR
- Timothy Slate SEC
- Lisa Gray DRC
- Leon Davies NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 18th, 2003
- Public Since
- July 28th, 2003
- No. of Shareholders
- 9,073
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 11,347,155
- Address
- Level 3, 101 St Georges Terrace, PERTH, 6000
- Web
- https://zeliratx.com/home/
- Phone
- +61 865580886
- Contact
- Ronn Bechler
- Auditors
- HLB Mann Judd
Upcoming Events for ZLD
Similar to ZLD
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Zelira Therapeutics share price?
As of Today at 19:24 UTC, shares in Zelira Therapeutics are trading at AU$0.69. This share price information is delayed by 15 minutes.
How has the Zelira Therapeutics share price performed this year?
Shares in Zelira Therapeutics last closed at AU$0.69 and the price had moved by -33.65% over the past 365 days. In terms of relative price strength the Zelira Therapeutics share price has underperformed the ASX All Ordinaries Index by -38.2% over the past year.
What are the analyst and broker recommendations for Zelira Therapeutics?
The overall consensus recommendation for Zelira Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zelira Therapeutics dividend yield?
Zelira Therapeutics does not currently pay a dividend.
Does Zelira Therapeutics pay a dividend?
Zelira Therapeutics does not currently pay a dividend.
When does Zelira Therapeutics next pay dividends?
Zelira Therapeutics does not currently pay a dividend.
How do I buy Zelira Therapeutics shares?
To buy shares in Zelira Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zelira Therapeutics?
As of the previous close price of AU$0.69, shares in Zelira Therapeutics had a market capitalisation of AU$7.83m.
Where are Zelira Therapeutics shares listed?
Here are the trading details for Zelira Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ZLD
What kind of share is Zelira Therapeutics?
Based on an overall assessment of its quality, value and momentum Zelira Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zelira Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Zelira Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zelira Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -32.25%.
As of the last closing price of AU$0.69, shares in Zelira Therapeutics were trading -34.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zelira Therapeutics PE Ratio?
The Zelira Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zelira Therapeutics?
Zelira Therapeutics' management team is headed by:
- Osagie Imasogie - CHM
- Harry Karelis - VCH
- Oludare Odumosu - MDR
- Timothy Slate - SEC
- Lisa Gray - DRC
- Leon Davies - NED